Lilly Highlights Latest Work in Diabetes Discovery and Development at 2014 European Association for the Study of Diabetes Annual Meeting (NYSE:LLY)

INDIANAPOLIS, Sept. 9, 2014 /PRNewswire/ -- Fifty abstracts designed to advance knowledge in diabetes science will be presented Sept. 15-19 by Eli Lilly and Company (NYSE: LLY) at the 50^th European Association for the Study of Diabetes (EASD) Annual Meeting. Notably, the company is highlighting two of its late-stage products: basal insulin peglispro and once-weekly dulaglutide. Twenty-eight of the abstracts will be presented as part of theBoehringer Ingelheim-Lilly Diabetes Alliance. EASD will take place in Vienna, Austria.



Lilly Highlights Latest Work in Diabetes Discovery and Development at 2014 European Association for the Study of Diabetes Annual Meeting (NYSE:LLY)